Guides Collective Get matched with a guide

Answers for the psychedelic-curious

Can I take psilocybin if I'm on SSRIs or antidepressants?

This is a question for the clinician who prescribed the medication — it is not one anyone can answer for you from the outside, including us. Three things are worth knowing before that conversation. SSRIs and SNRIs commonly blunt psilocybin's effects, sometimes for weeks or months after stopping. A few combinations are not merely blunting but genuinely risky — lithium and MAOIs above all. And stopping an antidepressant in order to "make it work" carries its own well-documented risks, which is precisely why it is a prescriber's decision and not a personal one.

By Troy Allen, Founder, Guides Collective Last updated: September 2, 2026

This is the single most common medication question we see from people considering a first experience, and it is usually asked in a place where nobody knows the person's history. What follows is context to bring to a clinical conversation — not a substitute for having one.

1. SSRIs and SNRIs usually dampen the experience

Both drug classes act on the serotonin system that psilocybin also works through, and long-term use appears to change how much of an effect a given dose produces.

A 2023 study of people who took psilocybin mushrooms during or after SSRI/SNRI treatment found weakened subjective effects, with the dampening reported as long as three months after discontinuing the antidepressant (Attenuation of psilocybin mushroom effects during and after SSRI/SNRI antidepressant use, 2023).

A 2025 qualitative analysis of naturalistic reports describing psilocybin or LSD alongside serotonergic antidepressants found the same broad pattern, with a wrinkle: in a subset of reports, sensory effects were reduced while emotional and mystical aspects of the experience stayed intact (Interactions between psilocybin, LSD, and serotonergic antidepressants, 2025). Clinically the picture is still mixed rather than settled — a 2025 consensus statement from the US National Network of Depression Centers reviews the open questions and cautions (eClinicalMedicine, 2025).

The practical consequence is the part people miss: a blunted response is exactly the situation in which someone takes more, which is the variable most consistently associated with difficult experiences. "It didn't work, so I doubled it" is how a medication interaction turns into a bad night.

2. Some combinations are risky, not just muted

Lithium. An analysis of 96 first- and second-person online reports of classic psychedelics taken with mood stabilisers found seizures described in 47% of the 62 lithium reports — and in none of the 34 lamotrigine reports (Nayak et al., Pharmacopsychiatry, 2021). The authors' provisional conclusion is that this combination poses a significant seizure risk. Self-reported data has real limits, but the signal is strong enough that clinicians treat lithium as a hard stop.

MAOIs (phenelzine, tranylcypromine, moclobemide and others) inhibit a secondary metabolic route for psilocybin and raise concerns about serotonin toxicity, hypertension and hyperthermia; research protocols require a long washout before administration for exactly this reason (Psychiatric Times: a clinician's guide to psilocybin interactions). Tramadol and other strongly serotonergic agents are also flagged in interaction reviews.

Medication class	What the literature describes
SSRIs / SNRIs	Commonly attenuated effects, potentially persisting weeks to months after stopping. Not generally described as acutely dangerous, but changes the picture substantially.
MAOIs	Serotonin toxicity, hypertension and hyperthermia concerns. Long washout required in research settings.
Lithium	Seizures and other serious adverse events reported. Treated as a contraindication.
Lamotrigine	No seizures or bad trips described in the same report analysis — a contrast the authors draw explicitly with lithium.
Tramadol, St John's wort, other serotonergic agents	Flagged in interaction reviews; belongs on the list you bring to a prescriber.

3. Stopping your medication is its own risk

People often arrive at this question having already decided the answer is "come off it for a while." That decision has consequences independent of psychedelics: discontinuation symptoms, and relapse of the condition the medication was treating. Those risks do not shrink because the reason for stopping is a planned experience, and the attenuation research suggests the effect may persist for months anyway — so a short taper may not even buy what someone hopes it will.

Do not stop, reduce, or reschedule a prescription on your own to prepare for a psychedelic experience. If coming off a medication is on the table, it belongs to the prescriber who put you on it, with a plan and a timeline. No guide, facilitator, retreat, or website — this one included — is in a position to advise on it.

4. What the supervised research looks like

Notably, staying on an antidepressant has been studied rather than assumed. An open-label phase II study administered a single 25 mg dose of a synthetic psilocybin formulation to 19 people with treatment-resistant depression who continued their SSRI, alongside psychological support. It was reported as tolerated with no serious adverse events, and 42% met response criteria at week three (Goodwin et al., Neuropsychopharmacology, 2023).

That is a small study, in a screened population, under medical supervision, with a known dose of a pharmaceutical-grade compound. It describes what is possible in a clinical setting; it does not describe unsupervised use, and it is not a green light. It is, however, a reasonable thing to raise with a prescriber who assumes the answer is automatically no.

How to have the conversation

Bring to your prescriber or physician:

A complete list of what you take — prescriptions, over-the-counter medicines, and supplements, including St John's wort.
What you are considering, and in what setting (a licensed program, a clinical trial, or a guided experience).
Personal and family history of bipolar disorder or psychosis, and any heart condition.
One direct question: is anything on this list a serotonergic interaction risk?

If your prescriber is unfamiliar with the area, a psychiatrist or pharmacist can often speak to the interaction question specifically. In Oregon's and Colorado's licensed programs, and with any competent guide, medication screening happens before anything else — and a guide who brushes the question aside is showing you how they will handle the next hard question too.

Screening should come before anything else

Guides Collective connects you with vetted guides who screen for medications and health history as part of the process — and every match starts with a free consultation, so you can ask the hard questions first.

Start the free 5-minute questionnaire

Private · No commitment · Not medical care

Frequently asked questions

Do SSRIs stop psilocybin from working?+

Not reliably, but they commonly blunt it. A 2023 study found weakened subjective effects during and after SSRI/SNRI use, with dampening reported as long as three months after stopping. A 2025 analysis of naturalistic reports found the same pattern, plus cases where sensory effects were reduced while emotional aspects stayed intact. The evidence is mixed and still developing.

Which combinations are actually dangerous?+

Lithium and MAOIs are the two clinicians treat as serious rather than merely blunting. In one analysis of 96 reports, seizures were described in 47% of 62 lithium cases and none of 34 lamotrigine cases. MAOIs raise serotonin-toxicity, hypertension and hyperthermia concerns, which is why trials require a long washout. Tramadol and other strongly serotonergic drugs are also flagged.

Should I stop my antidepressant first?+

Only your prescriber can answer that. Stopping or tapering carries discontinuation and relapse risks that do not go away because the reason is a planned experience — and the attenuation may persist for months regardless. No guide or website should be advising on it.

Has psilocybin been studied in people who stayed on their SSRI?+

Yes — an open-label phase II study gave a single 25 mg dose of a synthetic psilocybin formulation to 19 people with treatment-resistant depression who continued their SSRI, with psychological support. It was reported as tolerated with no serious adverse events and 42% response at week three. Small, screened, and medically supervised; not a description of unsupervised use.

Will a program or guide work with me if I'm on an antidepressant?+

It depends on the medication and the program, and that is what the screening conversation decides. A trained guide or licensed facilitator asks what you take before anything else, and should be willing to send you to your prescriber first — or to decline until you have gone.

What should I bring to the conversation with my prescriber?+

Everything you take, including over-the-counter medicines and supplements such as St John's wort; what you are considering and in what setting; family history of bipolar disorder or psychosis; and any heart condition. Then ask directly whether anything on the list is a serotonergic interaction risk.

Sources

Guides Collective is an informational platform that helps adults explore profiles of independent psychedelic guides. It is not a medical or mental-health provider and does not provide therapy, medical care, or psychedelic services.

All guides operate independently and are not employees, contractors, or agents of Guides Collective. Guides Collective does not verify guide-provided descriptions or credentials, does not recommend, endorse, or supervise any guide or service, and does not oversee or participate in any services guides offer.

Guides Collective does not provide or facilitate access to any substances. Each guide is solely responsible for their own services, communications, and compliance with local laws. Users are responsible for evaluating whether a guide's experience and approach are appropriate for their situation. No specific outcomes are promised or guaranteed.

Educational information on this page is provided for context only and does not constitute medical advice, diagnosis, treatment, or therapeutic claims. It is not guidance on starting, stopping, or changing any medication — those decisions belong with a licensed prescriber. Research findings describe study populations and do not predict individual outcomes. If you are in crisis, call or text 988 (U.S.).